Cargando…
Alterations in metabolic pathways and networks in Alzheimer's disease
The pathogenic mechanisms of Alzheimer's disease (AD) remain largely unknown and clinical trials have not demonstrated significant benefit. Biochemical characterization of AD and its prodromal phase may provide new diagnostic and therapeutic insights. We used targeted metabolomics platform to p...
Autores principales: | Kaddurah-Daouk, R, Zhu, H, Sharma, S, Bogdanov, M, Rozen, S G, Matson, W, Oki, N O, Motsinger-Reif, A A, Churchill, E, Lei, Z, Appleby, D, Kling, M A, Trojanowski, J Q, Doraiswamy, P M, Arnold, S E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641405/ https://www.ncbi.nlm.nih.gov/pubmed/23571809 http://dx.doi.org/10.1038/tp.2013.18 |
Ejemplares similares
-
Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging
por: Motsinger-Reif, Alison A, et al.
Publicado: (2013) -
Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
por: Kaddurah-Daouk, R, et al.
Publicado: (2011) -
Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics
por: Han, Xianlin, et al.
Publicado: (2011) -
ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease
por: Ko, Yi-An, et al.
Publicado: (2022) -
Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers
por: Nho, Kwangsik, et al.
Publicado: (2019)